A comprehensive view of U.S. Food and Drug Administration (FDA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves GSKs oral Jesduvroq daprodustat to treat anemia caused by chronic kidney disease in adults who have received dialysis for at least four months; CKD affect about 700 million patients worldwide, with one in seven developing anemia
Published: February 03, 2023 by GSK Group (GlaxoSmithKline)
Bausch + Lomb and Modulight announce FDA approval of ML6710i photodynamic laser for use with Bausch + Lomb's Visudyne verteporfin injectable; ML6710i is an easy-to-use, transportable ophthalmic laser controlled from an iPad mobile application
Published: February 03, 2023 by ENP Newswire
FDA to convene advisors to review experimental RSV vaccine candidate from Pfizer on February 28; group to meet in March to reviews RSV vaccine candidate from GSK
Published: February 03, 2023 by BioPharma Dive
FDA approves AstraZeneca and Amgen’s Tezspire tezepelumab in a pre-filled, single-use pen for patients aged 12 and older with severe asthma; Tezspire is the only biologic approved for severe asthma with no phenotype for use at home or doctor’s office
Published: February 02, 2023 by AstraZeneca AB
Amgen Launches Amjevita, a biosimilar to AbbVie's Humira adalimumab, in US to treat seven inflammatory diseases including moderate-to-severe rheumatoid arthritis in adults; Amjevita’s wholesale acquisition cost is 55% below current Humira list price
Published: February 02, 2023 by Mondaq Business Briefing

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count